MH
MHTX.US Manhattan Scients
- Market cap
- USD 55.9K
- P/E
- -
- P/B
- 15.64x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2024.
Is MHTX.US undervalued?
Graham numberThe Graham number of Manhattan Scients cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Manhattan Scients fundamental analysis
No fundamental analysis for Manhattan Scients yet.
Manhattan Scients stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Manhattan Scients
Manhattan Scientifics, Inc., a technology incubator, engages in the acquisition, development, and commercialization of life-enhancing technologies in the United States. It develops technologies in the areas of nano-technologies and nano-medicine. The company also offers nanostructured bulk metals and alloys in the form of rod, bar, wire, and foil for medical implants and other applications. The company was formerly known as Grand Enterprises, Inc. Manhattan Scientifics, Inc.…
Full company profileManhattan Scients financial statements
2024 annualized: Fiscal year 2024 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2024, the balance sheet is the latest quarter. Figures change when the annual report is published.
Manhattan Scients annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 642K | 64.0K | 150K | 142K | 0.00 | 97.0K | 50.0K | 50.0K | 50.0K | 0.00 | 4.00K |
| Gross Profit | 642K | 64.0K | 107K | -47.0K | -7.00K | 97.0K | 50.0K | 50.0K | 50.0K | -1.00K | - |
| Operating Income | -3.47M | -6.25M | -6.38M | -2.28M | -1.45M | -1.03M | -675K | -687K | -679K | -703K | -704K |
| EBITDA | -3.27M | 9.48M | -4.63M | -1.42M | -7.71M | -1.22M | 4.34M | -3.61M | -2.71M | -1.16M | -700K |
| Net Income | -3.81M | 8.01M | -6.11M | 1.55M | -8.33M | -1.22M | 4.31M | -3.64M | -2.73M | -1.17M | -1.08M |
| EPS | -0.01 | 0.01 | -0.01 | 0.00 | -0.02 | 0.00 | 0.01 | -0.01 | 0.00 | 0.00 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 3.63M | 12.9M | 7.64M | 10.8M | 2.66M | 2.23M | 6.85M | 3.45M | 1.03M | 316K | 74.0K |
| Total Liabilities | 4.47M | 4.28M | 4.91M | 2.69M | 2.81M | 3.23M | 2.17M | 2.42M | 2.73M | 2.12M | 2.42M |
| Shareholders' Equity | -832K | 8.59M | 2.72M | 8.16M | -150K | -1.01M | 4.67M | 1.04M | -1.70M | -1.80M | -2.34M |
| Cash & Short-term Investments | 2.53M | 5.36M | 1.07M | 269K | 87.0K | 261K | 353K | 232K | 175K | 67.0K | 38.0K |
| Total Debt | 2.96M | 2.38M | 2.41M | - | - | 78.0K | 104K | 130K | 110K | 60.0K | 60.0K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -2.54M | 3.42M | -4.56M | -791K | -682K | -316K | -388K | -421K | -349K | -190K | -118K |
| Capital Expenditure | 36.0K | 255K | 13.0K | 8.00K | 4.00K | 4.00K | 4.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -2.57M | 3.16M | -4.57M | -799K | -682K | -316K | -392K | -421K | -349K | -190K | -118K |
| Ratios | |||||||||||
| ROE | - | 93.2% | -224.3% | 18.9% | - | - | 92.3% | -351.6% | - | - | - |
| ROA | -104.7% | 62.3% | -80.0% | 14.3% | -313.3% | -54.9% | 63.0% | -105.4% | -264.8% | -368.7% | -1,459.5% |
| Net Profit Margin | -592.7% | 12,518.8% | -4,072.0% | 1,088.7% | - | -1,259.8% | 8,628.0% | -7,278.0% | -5,460.0% | - | -27,000.0% |
| Debt to Equity | - | 0.28x | 0.89x | - | - | - | 0.02x | 0.13x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Manhattan Scients dividends
Manhattan Scients has not paid dividends in the last 9 fiscal years.
Last stock split: 11001:1000 on Jan 9, 1998.
Who owns Manhattan Scients
Ownership data of Manhattan Scients is not available yet.
Manhattan Scients company profile
- Company name
- Manhattan Scients
- Ticker
- MHTX.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- 244 Fifth Avenue, New York, NY, United States, 10001
- Phone
- 212 541 2405
- Website
- mhtx.com
About Manhattan Scients
Manhattan Scientifics, Inc., a technology incubator, engages in the acquisition, development, and commercialization of life-enhancing technologies in the United States. It develops technologies in the areas of nano-technologies and nano-medicine. The company also offers nanostructured bulk metals and alloys in the form of rod, bar, wire, and foil for medical implants and other applications. The company was formerly known as Grand Enterprises, Inc. Manhattan Scientifics, Inc. was founded in 1992 and is based in New York, New York.
Manhattan Scients management
4- Mr. Marvin MaslowFounder & Chairman of the Board · born 1938
- Mr. Emmanuel TsoupanariasPresident, CEO & Director · born 1953
- Mr. Leonard C. FriedmanSecretary · born 1938
- Mr. Robert Romeo ProulxPresident of Imagion · born 1958